BeLiver
@beliver-bio.bsky.social
Reinventing the selection of optimal cancer treatments.
From Bordeaux in 🇫🇷
https://beliver.fr
https://www.linkedin.com/company/beliverfr/
From Bordeaux in 🇫🇷
https://beliver.fr
https://www.linkedin.com/company/beliverfr/
Learn more at www.beliver.fr and www.linkedin.com/company/beli...
April 15, 2025 at 5:57 PM
Learn more at www.beliver.fr and www.linkedin.com/company/beli...
Read more about the science behind our tech in our recent preprint: "Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments"
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments
Purpose Hepatocellular carcinoma (HCC) is the most common form of liver cancer with a bad prognosis in case of advanced HCC, only eligible for palliative systemic therapies. After a decade of exclusiv...
www.biorxiv.org
April 15, 2025 at 5:41 PM
Read more about the science behind our tech in our recent preprint: "Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments"
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...